To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Tislelizumab
Indication/Tumor Type esophagus squamous cell carcinoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive esophagus squamous cell carcinoma sensitive Tislelizumab Clinical Study - Cohort Actionable In a Phase III trial (RATIONALE-302), second-line Tevimbra (tislelizumab) improved median overall survival (mOS) (8.6 vs 6.3 mo; HR 0.70, p=0.0001) and objective response rate (20.3% vs 9.8%) compared to chemotherapy in advanced esophageal squamous cell carcinoma patients, and CD274 (PD-L1)-positive (TAP>=10%) patients treated with Tevimbra (tislelizumab) (n=89) showed improved mOS (10.3 vs 6.8 mo; HR 0.54, p=0.0006) compared to those patients treated with chemotherapy (n=68) (PMID: 35442766; NCT03430843). 35442766
CD274 positive esophagus squamous cell carcinoma sensitive Tislelizumab Guideline Actionable Tevimbra (tislelizumab) in combination with chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing CD274 (PD-L1, TAP >/= 5%) (PMID: 39986705; ESMO.org). 39986705 detail...
PubMed Id Reference Title Details
ESMO Clinical Practice Guidelines Full reference...
(35442766) Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. Full reference...
(39986705) ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma. Full reference...